natgillin/translations-raw huggingface dataset:
adjustment of Cch l and of Clan l by adding to the formulation obtained in step b) the amount of free macrocyclic chelate necessary, firstly, to complete the complexation of the free lanthanide so as to obtain Clan l = 0, and, secondly, to obtain Cch l = Ct ch l, wherein Ct ch l is the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation and is selected in the range of between 0.002 % and 0.4 % mol/mol, wherein the amount of free macrocyclic chelate in the final liquid pharmaceutical formulation corresponds to the proportion of free macrocyclic chelate relative to the amount of complexed macrocyclic chelate in the final liquid pharmaceutical formulation. 
podešavanje Cch 1 i Clan 1 pomoću dodavanja u formulaciju dobivenu u koraku b) potrebne količine slobodnog makrocikličkog kelata, prvo, da se okonča kompleksiranje slobodnog lantanida tako da se dobije Clan 1 = 0, te drugo, da se dobije Cch 1 = Ct ch 1, pri čemu Ct ch 1 je ciljana koncentracija slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji, te je odabrana u rasponu od između 0.002 % i 0.4 % mol/mol, pri čemu količina slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji odgovara udjelu slobodnog makrocikličkog kelata u odnosu na količinu kompleksiranog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji.
Process according to claim 11, characterized in that the amount of calcium in the liquid pharmaceutical formulation is less than 50 ppm and in that the amount of calcium in the ingredients used for the pharmaceutical solution, namely the chelate powder, in particular DOTA, water and meglumine, is less than 50 ppm, advantageously less than 20 ppm. 
Postupak prema zahtjevu 11, naznačen time da je količina kalcija u tekućoj farmaceutskoj formulaciji manja od 50 ppm i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu, odnosno u kelatnom prahu, naročito DOTA, vodi i megluminu, manja od 50 ppm, poželjno manja od 20 ppm.
Process according to any of claims 1 to 14, characterized in that an agent for blocking the free lanthanide, advantageously polycarboxylic acid, is added in step b). 
Postupak prema bilo kojem zahtjevu od 1 do 14, naznačen time da se sredstvo za blokiranje slobodnog lantanida, poželjno polikarboksilna kiselina, dodaje u koraku b).
A biomass gasification process including a biomass pyrolysis process according to any one of claims 1 to 5 wherein vapour and/or gaseous products of the biomass pyrolysis process are provided to an inlet of a biomass gasification process. 
Postupak plinofikacije koji obuhvaća postupak pirolize biomase prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se parni i/ili plinoviti produkti iz postupka pirolize biomase dobivaju na ulaznom dijelu postupka plinofikacije biomase.
preparation of a liquid pharmaceutical composition containing the complex of macrocyclic chelate with a lanthanide, free macrocyclic chelate that is not under the form of an excipient X[X',L] in which L is the macrocyclic chelate and X and X' are a metal ion, in particular chosen independently from calcium, sodium, zinc and magnesium, and/or free lanthanide, said step b) consisting in the preparation of a solid complex [chelate-lanthanide] and in the dissolution of the said complex in water; 
pripravu tekućeg farmaceutskog pripravka koji sadrži kompleks makrocikličkog kelata s lantanidom, te slobodni makrociklički kelat koji nije u obliku pomoćne tvari X[X',L] gdje L je makrociklički kelat i X i X' su metalni ion, naročito odabran neovisno od kalcija, natrija, cinka i magnezija, i slobodnog lantanida, pomoću miješanja otopine slobodnog makrocikličkog kelata i slobodnog lantanida, tako da se dobije kompleksiranje lantanida pomoću makrocikličkog kelata, te su količine slobodnog makrocikličkog kelata i slobodnog lantanida takve da sav lantanid ne kompleksira;
measurement in the pharmaceutical formulation obtained in step b) of the concentration of free macrocyclic chelate Cch 1 and/or of free lanthanide Clan 1; 
mjerenje u farmaceutskoj formulaciji dobivenoj u koraku b) koncentracije slobodnog lantanida Clan 1; a koncentracija slobodnog makrocikličkog kelata Cch1 jednaka je 0;
if Clan 1 = 0 and Cch 1 > Ct ch 1, free lanthanide, so as to obtain Cch 1 = Ct ch 1 and Clan 1 = 0 with Ct ch 1 representing the target concentration of the free macrocyclic chelate in the final liquid pharmaceutical formulation, Ct ch 1 being selected in the range of between 0.002 % and 0.4 % mol/mol, wherein the amount of free macrocyclic chelate in the final liquid pharmaceutical formulation corresponds to the proportion of free macrocyclic chelate relative to the amount of complexed macrocyclic chelate DOTA-Gd in the final liquid pharmaceutical formulation in mol/mol, and wherein the macrocyclic chelate is DOTA and the lanthanide is gadolinium. 
podešavanje Cch 1 i Clan 1 pomoću dodavanja u formulaciju dobivenu u koraku b) potrebne količine slobodnog makrocikličkog kelata, prvo, da se okonča kompleksiranje slobodnog lantanida tako da se dobije Clan 1 = 0, te drugo, da se dobije Cch 1 = Ct ch 1, pri čemu Ct ch 1 je ciljana koncentracija slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji, te je odabrana u rasponu od između 0.002 % i 0.4 % mol/mol, pri čemu količina slobodnog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji odgovara udjelu slobodnog makrocikličkog kelata u odnosu na količinu kompleksiranog makrocikličkog kelata u konačnoj tekućoj farmaceutskoj formulaciji.
Process according to claim 8, characterized in that the amount of calcium in the liquid pharmaceutical formulation to be administered to the patient is less than 50 ppm and in that the amount of calcium in the ingredients used for the pharmaceutical solution in step b), namely the DOTA powder, water and meglumine, is less than 20 ppm, advantageously less than 15 ppm. 
Postupak prema zahtjevu 11, naznačen time da je količina kalcija u tekućoj farmaceutskoj formulaciji manja od 50 ppm i time da je količina kalcija u sastojcima koji se koriste za farmaceutsku otopinu, odnosno u kelatnom prahu, naročito DOTA, vodi i megluminu, manja od 50 ppm, poželjno manja od 20 ppm.
fibrillating the cellulose fibres in an aqueous environment in the presence of the at least one filler and/or pigment until a nano-fibrillar cellulose gel is formed, wherein formation of the gels is verified by monitoring the viscosity of the mixture in dependence of the shearing rate, wherein the viscosity decrease of the mixture upon stepwise increase of the shearing rate is stronger than the corresponding viscosity increase upon subsequent step-wise reduction of the shearing rate over at least part of the shear rate range as shearing approaches zero; 
fibrilacije celuloznih vlakana u prisutnosti barem jednog punila i/ili pigmenta sve dok nema preostalih vlakana i stvaranje nano-vlaknastog gela samo sa primarnim vlaknima u vodenom okruženju, pri čemu se stvaranje gela provjerava promatranjem viskoznosti smjese u ovisnosti o brzini smicanja, pri čemu se viskoznost smjese smanjuje nakon što je stepeničasto povećanje brzine smicanja veće od odgovarajućeg povećanja viskoznosti poslije naknadnog stepeničastog smanjenja brzine smicanja tijekom barem dijela raspona brzine smicanja dok se smicanje približava nuli;
The RNA molecule of claim 1, further comprising a 3′ end having at least 20 consecutive A nucleotides, at least 40 consecutive A nucleotides, at least 80 consecutive A nucleotides, at least 100 consecutive A nucleotides, or about 120 consecutive A nucleotides. 
Molekula nukleinske kiseline prema zahtjevu 1 ili 2, pri čemu sekvenca nukleinske kiseline (c), pri transkripciji pod kontrolom promotora (a), kodira nukleotidnu sekvencu od najmanje 40, najmanje 80, najmanje 100, poželjno oko 120 uzastopnih A nukleotida u transkriptu.
A method according to claim 1, characterized in that the thickness of the layers of the insulation (13) of the voltage coil (10) decreases with the increase in their distance to the coil axis. 
Postupak prema zahtjevu 1, naznačen time, da se debljina slojeva izolacije (13) naponske navojnice (10) s povećanjem razmaka od osi navojnice, smanjuje.
A method according to claim 1 or 2, characterized in that after the completion of the process of banding the voltage coil (10) together with the top screen (17), a winding layer of semiconducting paper forming an external screen of the voltage coil is applied on the external surface of the main insulation of the instrument transformer (21) of the banded coil (10). 
Postupak prema zahtjevima 1 ili 2, naznačen time, da nakon završetka postupka koji naponsku navojnicu (10) spaja s gornjom zaštitom (17), na vanjsku površinu glavne izolacije instrumentnog transformatora (21) zajedno povezanih naponskih navojnica (10) bude pričvršćen jedan obavijajući sloj iz papira-poluvodiča, koji tvori vanjsku zaštitu naponske navojnice.
A method according to claim 3, characterized in that, following the application of the external screen on the main insulation of the instrument transformer (21) of the banded coil (10), the external screen is enveloped in copper strap. 
Postupak prema zahtjevu 3, naznačen time, da nakon nanošenja vanjske zaštite na glavnu izolaciju instrumentnog transformatora (21) zajedno povezane navojnice (10), vanjska zaštita bude omotana bakrenom trakom.
A device according to claim 7 characterized in that there are distance disks (8) and pressing sleeves (7) situated at the end of the crossbar (6). 
Naprava prema zahtjevu 7, naznačena time, da su distantne pločice (8) i stezni rukavci (7) postavljeni na krajevima traverze (6).
A device according to claim 1, characterized in that there is a holder (9) with a clamping ring fastened to the body (2), for keeping the transformer bushing in vertical position. 
Naprava prema zahtjevima 7-9, naznačena time, da je držač (9) sa steznom obujmicom, pričvršćen na tijelu (2), da bi se pozicija provodnika transformatora držala u vertikalnoj poziciji.
A device according to claim 1, characterized in that it comprises a nut (4) for regulating the height of the frame (1) position. 
Naprava prema zahtjevima 7-10, naznačena time, da sadrži jednu navojnicu (4), da bi se mogla regulirati visina pozicije okvira (1).
The process according to claim 1, wherein the light fraction, after being separated from the gases, is mixed with the heavy fraction treated by means of microwave irradiation. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se laku frakciju, nakon odvajanja od plinova, pomiješa s teškom frakcijom obrađenom mikrovalnim zračenjem.
The process according to claim 1, wherein the separation of the crude oils is effected so as to have a heavy fraction having a residual water content not higher than 500 ppm. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se razdvajanje sirove nafte tako provodi da se dobije teška frakcija koja sadrži preostali sadržaj vode ne veći od 500 ppm.
The use of opioid antagonists according to claim 1 wherein the opioid antagonist such as naltrexone, naloxone or nalmefene is administred to the patient in an oral dosage form comprising a tablet, coated tablets, chewable tablets, dispersable tablets, rapid dissolve tablets, sublingual tablets, effervescent tablets, effervescent granules, dragees, capsules, sachets, cachets, caplets, lozenges, liposomes, powders, granules, powders for suspensions, powders for solutions, solutions, emulsions, liquids and syrups. 
Uporaba opioidnih antagonista prema zahtjevu 1 naznačena time da se opioidni antagonist kao što je naltrekson, nalokson ili nalmefen daje pacijentu u oralnom obliku doziranja koji čini tableta, obložene tablete, tablete za žvakanje, raspršive tablete, brzo topive tablete, sublingvalne tablete, šumeće tablete, šumeće granule, dražeje, kapsule, vrećice, škrobne kapsule, kaplete, pastile, liposomi, prašci, granule, prašci za suspenzije, prašci za otopine, otopine, emulzije, tekućine i sirupi.
The use of opioid antagonists according to claim 1 wherein the opioid antagonist such as naltrexone, naloxone or nalmefene is administred to the patient topically in the form of creams, ointments, gels, eye drops, lotions, suppositories and enemas. 
Uporaba opioidnih antagonista prema zahtjevu 1 naznačena time da se opioidni antagonist kao što je naltrekson, nalokson ili nalmefen daje pacijentu topikalno u obliku krema, masti, gelova, kapi za oči, losiona, čepića i klistira.
is selected from methyl or chloro; 
je odabran od metila ili kloro;
A compound according to Claim 1 or Claim 2 in the form of a pharmaceutically acceptable salt. 
Spoj prema zahtjevu 1 ili zahtjevu 2 naznačen time da je u obliku farmaceutski prihvatljive soli.
The use of a compound according to any one of claims 1, 2, 3 or 4 in the manufacture of a medicament for the therapy of neurological and psychiatric disorders associated with glutamate dysfunction. 
Uporaba spoja prema bilo kojem zahtjevu 1, 2, 3 ili 4 naznačena time da je za proizvodnju medikamenta za liječenje neuroloških i psihijatrijskih poremećaja povezanih s glutamatnom disfunkcijom.
The use of claim 7, wherein the disorder is schizophrenia. 
Uporaba prema zahtjevu 7, naznačena time da poremećaj je shizofrenija.
A compound as claimed in claim 1, 2, 3 or 4 for the treatment of neurological and psychiatric disorders associated with glutamate dysfunction. 
Spoj prema zahtjevu 1, 2, 3 ili 4 naznačen time da je za terapiju neuroloških i psihijatrijskih poremećaja povezanih s glutamatnom disfunkcijom.
The treatment of claim 9, wherein the neurological and psychiatric disorder is schizophrenia. 
Terapija prema zahtjevu 9, naznačena time da neurološki i psihijatrijski poremećaj je shizofrenija.
The compound according to claim 7, wherein the substance is nicotine. 
Uporaba prema zahtjevu 7, naznačena time da poremećaj je shizofrenija.
A therapeutic antibody according to claim 10 in which residues 235 and 237 have been mutated to alanine 
Terapijsko protutijelo u skladu s patentnim zahtjevom 5, naznačeno time što su ostaci 235 i 237 imitirani u alanin.
A pharmaceutical composition comprising a therapeutic antibody according to any preceding claim. A therapeutic antibody according to any one of claims 1 to 7 for use in the treatment of a β-amyloid peptide-related disease. 
Terapijsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7, namijenjeno upotrebi u liječenju bolesti, naznačeno time što su za navedenu bolest karakteristične povišene razine P-amiloida ili naslage P-amiloida.
The spatial logical game according to Claims 1 or 2, characterised in that the body (201) consists of three body portions (202, 203, 204). 
Igra prostorne logike u skladu s patentnim zahtjevom 1 ili 2, karakterizirana time što se tijelo (201) sastoji od tri dijela tijela (202, 203, 204).
The spatial logical game according to Claim 10, characterised in that the outer surface of the terminal portions (206, 208) adapted for allowing the grabbing and displacing the internal and middle body portions (202, 203) is shaped to correspond to the outer shape of the external body portion (204). 
Igra prostorne logike u skladu s patentnim zahtjevom 10, karakterizirana time što je vanjska površina krajnjih dijelova (206, 208) prilagođena za omogućavanje hvatanja i odmicanja unutarnjeg i srednjeg dijela tijela (202, 203) oblikovana da odgovara vanjskom obliku izvanjskog dijela tijela (204).
The spatial logical game according to Claims 1 or 2, characterised in that it has path sections extending along spatial curves. 
Igra prostorne logike u skladu s patentnim zahtjevom 1 ili 2, karakterizirana time što ima odjeljke putanje koji se protežu duž prostornih krivulja.
The spatial logical game according to Claims 1 or 2, characterised in that the toy element (7) thereof is a branching element, or has multiple heads, heads having different configuration, or has a curved stem, where the body portions, when indicated, consist of multiple subportions. 
Igra prostorne logike u skladu s patentnim zahtjevom 1 ili 2, karakterizirana time što je njen element igračke (7) razgranati element, ili ima višestruke glave, glave imaju različite konfiguracije, ili imaju zakrivljen držak, gdje se dijelovi tijela, kada je to naznačeno, sastoje od višestrukih poddijelova.
A closure (10) as claimed in claim 8, in which the locking bead (57) is segmented. 
Zatvarač (10) prema zahtjevu 8, gdje je kuglica za zaključavanje (57) segmentirana.
A closure (10) as claimed in Claim 10, in which the notch extends over substantially the full height of the inner skirt (50). 
Zatvarač (10) prema zahtjevu 10, gdje se usjek pruža preko u biti cijele visine unutarnjeg obruba (50).
a centrally located core (20, 38) provided with an upper side (38a) and a lower side (38b), 
centralno smještenu jezgru (20, 38) s gornjom stranom (38a) i donjom stranom (38b),
Floor panel (19, 24, 37, 41, 52, 70, 88, 97, 106, 114) as claimed in any of the foregoing claims, wherein the first locking element (31, 44, 53, 71) is positioned at a distance from an upper side (41d) of the upward tongue (25, 41, 56, 73). 
Podni panel (24, 37, 41, 52, 70, 106, 114) prema bilo kojem od prethodnih zahtjeva, gdje je prvi element zaključavanja (31, 44, 53, 71) smješten na udaljenosti od gornje strane (41d) uvis okrenutog jezičca (25, 41, 56, 73).
Floor panel (19, 24, 37, 41, 52, 70, 88, 97, 106, 114) as claimed in any of the foregoing claims, wherein the second locking element (32, 49, 56, 74, 92) is positioned at a distance from an upper side (48a) of the downward groove (30, 48). 
Podni panel (24, 37, 41, 52, 70, 88, 97, 106, 114) prema bilo kojem od prethodnih zahtjeva, gdje je drugi element zaključavanja (32, 49, 56, 74, 92) smješten na udaljenosti od gornje strane (48a) dolje okrenutog jezičca (30, 48).
Floor covering consisting of mutually coupled floor panels (24, 37, 41, 52, 70, 88, 97, 106, 114) as claimed in any of the claims 1-26. 
Podna obloga koja se sastoji od međusobno spojenih podnih panela (24, 37, 41, 52, 70, 88, 97, 106, 114) prema bilo kojem od zahtjeva 1-26.
A therapeutic antibody according to claim 1, wherein said antibody or antigen binding fragment and/or derivative thereof binds β-amyloid peptide 1-12 (SEQ ID No:15) with equilibrium constant KD less than 100pM and has an equilibrium constant KD for binding to β-amyloid peptide 2-13 (SEQ ID No:44) which is 1000-fold greater than that for peptide 1-12 (SEQ ID No:15), both determinations being made in a surface plasmon resonance assay utilising peptide captured on streptavidin chip. 
Terapijsko protutijelo u skladu s patentnim zahtjevom 1, naznačeno time što se navedeno protutijelo ili njegov antigenski vežući fragment i/ili derivat veže na P-amiloidni peptid 1-12 (SEQ ID No:15) uz konstantu ravnoteže KD manju od 100 pM, te ima konstantu ravnoteže KD za vezanje na β-amiloidni peptid 2-13 (SEQ ID No:44) koja je 1000 puta veća od one za peptid 1-12 (SEQ ID No:15), gdje su oba podatka dobivena ispitivanju površinskom plazmonskom rezonancijom uz upotrebu peptida vezanog na streptavidinski čip.
method B of the Examples). 
postupak B iz Primjera).
A therapeutic antibody according to any one of claims 1 to 7 for use in the treatment of a disease characterised by elevated β-amyloid levels or β-amyloid deposits. 
Terapijsko protutijelo u skladu s bilo kojim od patentnih zahtjeva 1 do 7, namijenjeno upotrebi u liječenju bolesti, naznačeno time što su za navedenu bolest karakteristične povišene razine P-amiloida ili naslage P-amiloida.
Floor covering consisting of mutually coupled floor panels (19, 24, 37, 41, 52, 70, 88, 97, 106, 114) as claimed in any of the foregoing claims. 
Podna obloga koja se sastoji od međusobno spojenih podnih panela (24, 37, 41, 52, 70, 88, 97, 106, 114) prema bilo kojem od zahtjeva 1-26.
A is optionally substituted heteroaryl; 
A je po izboru supstituirani heteroaril;
is optionally substituted carbocyclic; 
je po izboru supstituiran karbociklični prsten;
optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; 
opcijski supstituiran alkil, opcijski supstituiran alkenil, ili opcijski supstituirani alkinil, od kojih svaka sadrži 0, 1, 2, ili 3 heteroatoma izabrana od O, S, ili N;
wherein R' and R" together form an aryl ring; 
pri čemu R' i R" zajedno tvore arilni prsten;
An apparatus according to claim 1, wherein there are no other components than the flexible tube or rod (2) in the interior of the inflatable bladder (110). 
Uređaj prema zahtjevu 1, naznačen time da unutar mjehura koji se napuhuje (110) nema nikakvih drugih komponenti osim savitljive cijevi ili šipke (2).
An apparatus according to any of claims 1 to 3, wherein said push-pull-turn hose (5) is in fluidic connection with the interior of the inflatable bladder (110) via a conduit (25) in the proximal collar fitting (3). 
Uređaj prema bilo kojem od zahtjeva od 1 do 3, naznačen time da je spomenuto crijevo za potiskivanje-povlačenje-okretanje (5) protočno povezano s unutrašnjosti mjehura koji se napuhuje (110) preko voda (25) u proksimalnoj spojnici (3).
An apparatus according to any of claims 1 to 6, wherein the proximal collar fitting (3) and/or the distal collar fitting (4) comprises an area with ribs (17). 
Uređaj prema bilo kojem od zahtjeva 1 do 6, naznačen time da proksimalna spojnica (3) i/ili distalna spojnica (4) imaju jednu površinu s rebrima (17).
a distal collar fitting (4) with a coupling half at one end, 
distalnu spojnicu (4) s polovicom spojnice na jednom kraju,
a small cross-sectional area flexible tube or rod (2) with a coupling half at both opposite ends that matches the coupling halves on the collar fittings, and 
savitljivu cijev male površine presjeka ili šipku (2) s polovicom spojnice na oba nasuprotna kraja koja se uklapa u polovice spojnice na spojnicama, i
A toolkit according to claim 13, wherein said inflatable bladders (110) are bladders with two open ends. 
Komplet alata prema zahtjevu 13, naznačen time da su spomenuti mjehuri koji se napuhuju (110) mjehuri s dva otvorena kraja.
A method of producing a compound of formula I, or a pharmaceutically acceptable salt thereof, comprising the step of reacting a compound of formula II: wherein, 
Postupak za proizvodnju spoja formule I, ili njegove farmaceutski prihvatljive soli, koji obuhvaća reakcijski korak spoja formule II:
PGN is an amino protecting group and PGC is a carboxylic acid protecting group; 
[image] naznačen time, da PGn je amino zaštitna skupina, a PGC je zaštitna skupina karboksilne kiseline;
optionally substituted carbocyclic; or 
po izboru supstituirani karbociklički prsten; ili
X and Y are selected from the group consisting of hydrogen, methyl, fluoro, chloro, trifluoromethyl, methoxy, trifluoromethoxy, morpholin-4-yl-methanone such that not two of the subtituents are hydrogen at the same time; 
X i Y se bira iz skupine koju čine vodik, metil, fluor, klor, trifluormetil, metoksi, trifluormetoksi, morfolin-4-il-metanon, gdje dva supstituenta nisu istodobno vodici;
is selected from the group comprising, hydrogen and natural and unnatural amino acids; an N-oxide of said compound, a pharmaceutically acceptable salt of said compound, a solvate of said compound or a hydrate of said compound. 
se bira iz skupine koju čine vodik, te prirodne i sintetske aminokiseline; N-oksid navedenog spoja, farmaceutski prihvatljiva sol navedenog spoja, solvat navedenog spoja ili hidrat navedenog spoja.
The compound in claim 1 wherein R2 is selected from the group consisting of hydrogen and -C(O)CH(CH(CH3)2)NH2. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se R2 bira iz skupine koju čine vodik i -C(O)CH(CH(CH3)2)NH2.
The compound in claim 1 which is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što se bira iz skupine koju čine:
The pharmaceutical composition in claim 10 wherein said one or more additional pharmaceutically active compounds are chosen from the group consisting of compounds known to treat airway inflammation. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što se navedeni jedan ili više dodatnih farmaceutski aktivnih spojeva bira iz skupine koju čine spojevi poznati u liječenju upale dišnih putova.